Alnylam Pharmaceuticals Inc. (ALNY) Coverage Initiated by Analysts at Janney Montgomery Scott
Janney Montgomery Scott started coverage on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a research note released on Wednesday morning. The brokerage issued a neutral rating and a $74.00 price objective on the biopharmaceutical company’s stock.
Several other brokerages also recently issued reports on ALNY. Jefferies Group reiterated a buy rating and set a $80.00 price target (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, June 8th. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 25th. FBR & Co reiterated an outperform rating and set a $180.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Morgan Stanley set a $93.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, September 6th. Finally, Chardan Capital reiterated a buy rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 11th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $110.79.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 76.67 on Wednesday. Alnylam Pharmaceuticals has a 12-month low of $49.96 and a 12-month high of $110.75. The company’s 50-day moving average is $73.60 and its 200-day moving average is $66.18. The firm’s market capitalization is $6.57 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter in the prior year, the firm earned ($0.85) EPS. The firm’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.65) earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.00% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $56,311,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of Alnylam Pharmaceuticals by 8.8% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 23,473 shares of the biopharmaceutical company’s stock valued at $1,473,000 after buying an additional 1,892 shares in the last quarter. Aperio Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 8,328 shares in the last quarter. Parametrica Management Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at about $205,000. Finally, Pacad Investment Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at about $490,000. 85.96% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.